Harrison SJ - Search Results

1

Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis.

Dimopoulos MA, Leleu X, Moreau P, Richardson PG, Liberati AM, Harrison SJ, Miles Prince H, Ocio EM, Assadourian S, Campana F, Malinge L, Sémiond D, van de Velde H, Yong K. Dimopoulos MA, et al. Among authors: harrison sj. Leukemia. 2021 Feb;35(2):562-572. doi: 10.1038/s41375-020-0868-z. Epub 2020 May 23. Leukemia. 2021. PMID: 32444867 Free PMC article. Clinical Trial.

2

The potential of histone deacetylase inhibitors for the treatment of multiple myeloma.

Prince HM, Bishton M, Harrison S. Prince HM, et al. Leuk Lymphoma. 2008 Mar;49(3):385-7. doi: 10.1080/10428190801950058. Leuk Lymphoma. 2008. PMID: 18297514

3

The development of novel immunotherapeutic approaches in multiple myeloma.

Peinert S, Prince HM, Harrison S. Peinert S, et al. Leuk Lymphoma. 2008 Apr;49(4):652-4. doi: 10.1080/10428190802007742. Leuk Lymphoma. 2008. PMID: 18398729 Review. No abstract available.

4

Enumeration of blood dendritic cells in patients with multiple myeloma at presentation and through therapy.

Harrison SJ, Franklin IM, Campbell JD. Harrison SJ, et al. Leuk Lymphoma. 2008 Dec;49(12):2272-83. doi: 10.1080/10428190802464729. Leuk Lymphoma. 2008. PMID: 19052974

5

Predicting durable remissions following thalidomide therapy for relapsed myeloma.

Quach H, Mileshkin L, Seymour JF, Milner A, Ritchie D, Harrison S, Westerman D, Prince HM. Quach H, et al. Leuk Lymphoma. 2009 Feb;50(2):223-9. doi: 10.1080/10428190802663213. Leuk Lymphoma. 2009. PMID: 19194832 Clinical Trial.

6

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.

Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ, Prince HM. Quach H, et al. Leukemia. 2010 Jan;24(1):22-32. doi: 10.1038/leu.2009.236. Epub 2009 Nov 12. Leukemia. 2010. PMID: 19907437 Free PMC article. Review.

7

A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.

Harrison SJ, Quach H, Link E, Seymour JF, Ritchie DS, Ruell S, Dean J, Januszewicz H, Johnstone R, Neeson P, Dickinson M, Nichols J, Prince HM. Harrison SJ, et al. Blood. 2011 Dec 8;118(24):6274-83. doi: 10.1182/blood-2011-03-339879. Epub 2011 Sep 12. Blood. 2011. PMID: 21911830 Free article. Clinical Trial.

8

Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma.

Doo NW, Thompson PA, Prince HM, Seymour JF, Ritchie D, Stokes K, Burbury K, Wolf M, Joyce T, Harrison SJ. Doo NW, et al. Among authors: harrison sj. Leuk Lymphoma. 2013 Jul;54(7):1465-72. doi: 10.3109/10428194.2012.746682. Epub 2012 Dec 14. Leuk Lymphoma. 2013. PMID: 23121086

9

A risk-adapted protocol for delayed administration of filgrastim after high-dose chemotherapy and autologous stem cell transplantation.

Khot A, Dickinson M, Stokes K, Harrison S, Burbury K, Fleming S, Wall D, Gambell P, Prince HM, Seymour JF, Ritchie D. Khot A, et al. Clin Lymphoma Myeloma Leuk. 2013 Feb;13(1):42-7. doi: 10.1016/j.clml.2012.09.017. Epub 2012 Nov 10. Clin Lymphoma Myeloma Leuk. 2013. PMID: 23146384

10

Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant.

Harrison SJ, Hsu AK, Neeson P, Younes A, Sureda A, Engert A, Prince HM, Li M, Savage P, Bugarini R, Williams D, Squier M, Ritchie DS. Harrison SJ, et al. Leuk Lymphoma. 2014 May;55(5):1053-60. doi: 10.3109/10428194.2013.820287. Epub 2013 Aug 5. Leuk Lymphoma. 2014. PMID: 23822537

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

289 results

Search Page